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1Atherosclerosis is an age-related systemic disease char-acterized by systemic oxidative stress and low-grade 
chronic inflammation, which is driven both by innate and 
adaptive immune responses. In particular, distinct subpopu-
lations of T-cells have opposing roles in the development of 
atherosclerotic lesions,1 and an imbalance between pathogenic 
and regulatory immunity influences plaque development and 
disease progression. We and others have shown previously that 
the majority of T-cells in an atherosclerotic lesion are CD4+ 
T-helper type 1 cells that produce interferon-γ2–12 and defi-
ciency in either interferon-γ or the transcription factor T-bet 
(required for T-helper type 1 differentiation) attenuates the 
progression of atherosclerosis in cholesterol-fed low-density 
lipoprotein receptor null mice (Ldlr–/–). Conversely, reduc-
tion or dysfunction of the regulatory T-cell population (T
reg) 
leads to increased atherosclerosis.5,13,14 Furthermore, adoptive 
transfer of the T
reg subpopulation into hypercholesterolemic 
mice reduces lesion development.5 Recently, it has also been 
demonstrated that prolonged hypercholesterolemia impairs 
T
reg cells but not effector T-cell accumulation in atheroscle-
rotic lesions and reversal of hypercholesterolemia can prevent 
loss of lesional T
reg cells.12 The ratio of regulatory to effec-
tor T-cells is, therefore, critical in determining the outcome of 
atherosclerosis.
Human T
reg cells do not arise solely from thymic gen-
eration but can also be induced by rapid turnover from the 
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Objective—Atherosclerosis is an age-related disease characterized by systemic oxidative stress and low-grade inflammation. 
The role of telomerase and telomere length in atherogenesis remains contentious. Short telomeres of peripheral leukocytes 
are predictive for coronary artery disease. Conversely, attenuated telomerase has been demonstrated to be protective for 
atherosclerosis. Hence, a potential causative role of telomerase in atherogenesis is critically debated.
Approach and Results—In this study, we used multiple mouse models to investigate the regulation of telomerase under 
oxidative stress as well as its impact on atherogenesis in vitro and in vivo. Using primary lymphocytes and myeloid 
cell cultures, we demonstrate that cultivation under hyperoxic conditions induced oxidative stress resulting in chronic 
activation of CD4+ cells and significantly reduced CD4+ T-cell proliferation. The latter was telomerase dependent because 
oxidative stress had no effect on the proliferation of primary lymphocytes isolated from telomerase knockout mice. In 
contrast, myeloid cell proliferation was unaffected by oxidative stress nor reliant on telomerase. Telomerase reverse 
transcriptase deficiency had no effect on regulatory T-cell (T
reg) numbers in vivo or suppressive function ex vivo. Adoptive 
transfer of telomerase reverse transcriptase–/– T
regs into Rag2–/– ApoE–/– double knockout mice demonstrated that telomerase 
function was not required for the ability of T
regs to protect against atherosclerosis. However, telomere length was critical 
for T
reg function.
Conclusions—Telomerase contributes to lymphocyte proliferation but plays no major role in T
reg function, provided 
that telomere length is not critically short. We suggest that oxidative stress may contribute to atherosclerosis via 
suppression of telomerase and acceleration of telomere attrition in T
regs.  (Arterioscler Thromb Vasc Biol. 2018;38:00-00. 
DOI: 10.1161/ATVBAHA.117.309940.)
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memory T-cell pool.15 Once generated, they are susceptible 
to apoptosis and have limited replicative potential, which is 
directly related to telomere length.16 Telomeres consist of 
tandem TTAGGG DNA repeats at the ends of chromosomes 
as well as the shelterin complex. They function to maintain 
chromosomal integrity during cell division and protect against 
chromosomal instability. In cells without telomerase activ-
ity, telomeres shorten with every cell division because of the 
end replication problem,17 as well as because of increased 
oxidative stress.18 Telomere shortening can be compensated 
or slowed down by concomitant activity of telomerase, a 
ribonucleoprotein composed of an RNA subunit (telomerase 
RNA component [TERC]), containing the template for telo-
mere repeat addition, and a telomerase reverse transcriptase 
(TERT) subunit. Accordingly, late-generation telomerase 
knockout mice (TERT−/− or TERC−/−) display an age-related 
phenotype.19–21
Regarding its specific role in T-lymphocytes, telomerase 
levels control the lifespan of T lymphocytes22 while telomere 
dysfunction in late-generation TERC−/− mice reduces the num-
ber and function of T- and B- lymphocytes.16,20,23,24 The end 
replication problem is not the only mechanism that can con-
tribute to telomere shortening resulting eventually in cellular 
senescence. Telomeres have been shown to be favored targets 
for DNA damage.25,26 Because oxidative stress plays a major 
role in chronic inflammatory diseases, it has been suggested 
that telomere damage may be involved in their pathophysiol-
ogy. However, the exact mechanisms driving telomere damage 
and shortening under conditions of chronic oxidative stress 
are still not fully understood.
Telomere length in leukocytes has been investigated in a 
variety of clinical studies involving patients with either exist-
ing or developing coronary heart disease (CHD).27–33 There 
remains a paucity of data on the role of telomerase and its 
regulation in atherosclerosis. The increased prevalence of ath-
erosclerosis in older people is associated with a decline in the 
function of lymphoid progenitors and mature T-cells,34 and 
shorter telomeres have been observed in leukocytes of human 
patients with advanced coronary atherosclerosis.35 However, 
it is unclear as to whether accelerated telomere shortening or 
inherited telomere length are the most important influences in 
the development of atherosclerosis.36,37
It has been previously suggested that telomere shortening 
and dysfunction in telomerase activity in leukocytes, includ-
ing T-cells, may be causative in the progression of this dis-
ease.29,31 This hypothesis, however, is in direct contradiction 
to the recent demonstration of Poch et al38 who have shown 
that a mouse model that lacks telomerase activity and dis-
plays significantly shorter telomeres is in fact protected from 
atherosclerosis,38 as well as the observations that aged rabbits 
develop less atheroma under a high-cholesterol diet compared 
with younger animals.39 Several human studies have also 
failed to identify any association between telomere length and 
atherosclerosis40 or between telomere length and mortality in 
subjects over the age of 65 years.41–43 However, it has been 
suggested that studies showing no correlation have examined 
older populations37 while until the age of 60 years there is 
a correlation between telomere length and mortality which 
includes cardiovascular deaths.44 Adding further complexity 
to the interpretation of the human studies is the fact that fac-
tors, including race/ethnicity and sex, all influence outcome.37
In this study, we aimed to address some of the contro-
versy surrounding the role of telomerase activity and telo-
mere length with regards to T-cell activation and proliferation. 
Moreover, we aimed to address the functional requirement of 
telomerase for regulatory T-cell–mediated atheroprotection. 
We report here that oxidative stress suppresses telomerase 
activity and attenuates proliferation of CD4+ T-lymphocytes 
but not CD11b+ myeloid cell expansion. Lack of Tert in cells 
with sufficiently long telomeres within a population of T
reg 
T-lymphocytes is not detrimental to their suppressive func-
tion. In contrast, short telomeres diminished T
reg number and 
function.
Methods
The data that support the findings of this study are available from 
the corresponding author on reasonable request. Details of the major 
resources and detailed methods can be found in the online-only Data 
Supplement.
Animals and Ethics
Animal work was authorized and approved by the Cambridge and 
Newcastle University Ethics review boards. All animal procedures 
were performed conforming to the guidelines from Directive 2010/63/
EU of the European Parliament on the protection of animals used for 
scientific purposes. Both male and female mice were used in all stud-
ies. TERT knockout, generated by Chiang et al45 (Jax strain B6.129S-
Tert tm1Yjc/J), and TERC knockout, generated by Blasco et al46 (Jax 
strain B6.Cg-Terc tm1Rdp/J), animals were purchased from Jackson 
Laboratory, Maine. Generation and initial phenotypic characteriza-
tion of the mTert-GFP (green fluorescent protein) mice have been 
published previously.47–51 The mTert-GFP mouse2 contains a reporter 
cassette in which the expression of the gene for GFP is under the 
control of a 4.4-kb fragment of the promoter of murine Tert. As such 
GFP expression in this model represents mTert promoter activity as 
an indicator of TERT transcription. Rag2−/− ApoE−/− double knock-
out mice and CD28−/− mice were originally obtained from Charles 
River. All mice were held under the UK Home office animal licenses 
PPL 60/3864 or PO11C464C. Details for each line used to obtain the 
data for each figure are included in Table I in the online-only Data 
Supplement.
Splenocyte and CD4 Cell Isolation, 
Culture, and Growth Curves
Cells were isolated and cultured as described previously.47 Assessment 
of CD4+ cell purity is demonstrated in Figure I in the online-only Data 
Supplement. Splenocytes were cultured in a 24-well plate (2×106 
cells/2 mL per well). MACSibead mouse T-cell, CD3 and CD28 anti-
body coated, expansion beads (Miltenyi 130-093-627) were added 
to medium as described.47 TA-65 activator (TA65) is a telomerase 
activator purified from Astragalus membranaceous52 and provided by 
TA-Science Inc (New York, NY). BIBR 1532 (Tocris Bioscience), a 
Nonstandard Abbreviations and Acronyms
CHD coronary heart disease
GFP green fluorescent protein
Treg regulatory T-cell
TERC telomerase RNA component
TERT telomerase reverse transcriptase
WT wild type
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telomerase inhibitor,53 was dissolved in dimethyl sulfoxide and used 
as the indicated concentration.
Dihydroethidium and Mitosox Staining
Dihydroethidium and Mitosox are established methods to measure 
superoxide levels.54,55
Telomeric Repeat Amplification Protocol 
Polymerase Chain Reaction ELISA
Telomeric Repeat Amplification Protocol kit (Roche) was performed 
as per the manufacturer’s instructions. TERT−/− splenocytes and the 
immortal fibroblast cell line 3T3 were used as negative and positive 
controls (Figure VI in the online-only Data Supplement).
Detection of T
reg
After isolation, splenocytes were labeled using the T
reg Detection Kit (Miltenyi Biotec, Auburn, CA) as per manufactures instructions. In 
our hands, ≥98% of CD4+ T-cells can be identified as T-cells by CD3+ 
staining (Figure V in the online-only Data Supplement).
Atherosclerosis Experiments
Rag2−/− ApoE−/− mice were transplanted with 107 splenocytes from 
CD28−/− mice and either PBS or 106 CD4+ CD25+ regulatory T-cells 
from either Tert−/− mice or wild-type (WT) littermates. Mice were 
fed an atherogenic Western diet (21% fat, 0.15% cholesterol) for 7 
weeks. Atherosclerosis was quantified in the aortic root as described 
previously.56
Statistical Analysis
After a test for normality, statistical analysis was performed as appro-
priate and indicated in the legend of each figure. Data are presented as 
mean±SEM or as dot for individual experiments with a line represent-
ing the median. A Mann–Whitney U test was used to compare groups 
of 2, and 2-way ANOVA with Bonferroni post hoc analysis was used 
to compare groups of ≥3. Statistical significance was set at P<0.05.
Results
Increased Oxidative Stress Results in Chronic 
T-Cell Activation and Reduced Proliferation
Increased oxidative stress and acute inflammation as well as 
increased T-cell activity are key characteristics of atheroscle-
rosis. We have previously established hyperoxia as a model 
of chronic mild oxidative stress.18,57,58 In this study, we used 
hyperoxic culture conditions to study the effect of chronic 
oxidative stress on lymphocyte growth kinetics and T-cell 
activation.
Splenocytes or CD4+ T-cells were cultured for 10 days at 
either physiological oxygen levels (physoxia, 3% oxygen) or 
hyperoxia (40% oxygen). Assessment of cell purity is shown 
in Figure I in the online-only Data Supplement. When cultured 
under hyperoxic conditions, both the total splenocyte popula-
tion and CD4+ T-cells displayed a significantly higher level 
of dihydroethidium staining intensity indicating increased 
mitochondrial superoxide levels (Figure 1A). Similar results 
for splenocytes cultured in high oxygen were obtained with 
another superoxide-specific probe Mitosox (Figure II in the 
online-only Data Supplement).
CD4+ cells cultured under hyperoxic conditions had an 
elevated interferon γ mRNA expression relative to splenoc-
tyes cultured at physoxia (Figure 1B). Increased interferon 
γ expression was observed throughout the culture duration, 
indicative of chronic T-cell activation, with a further increase 
at 6 days. High oxygen had a similar effect on the expres-
sion of interleukin 2 (Figure III in the online-only Data 
Supplement). Having demonstrated that hyperoxia and oxi-
dative stress are associated with aspects of T-cell activation, 
we were interested to examine the effect of oxidative stress 
on splenocyte proliferation. Splenocytes cultured at physoxia 
demonstrated a 30-fold increase in cell number over 28 days. 
In contrast, splenocytes cultured in either 20% or 40% oxygen 
saturation showed a dose-dependent attenuation of prolifera-
tion by 15% or 50%, respectively, compared with physoxia 
(P<0.0001; Figure 1C).
Given the heterogeneity of cell populations residing in 
the spleen, flow cytometry was used to study the effect of 
oxidative stress on the proliferation of individual splenocyte 
subpopulations (Figure 1D–1F). Gating strategy and con-
trols shown in Figure IVA and IVB in the online-only Data 
Supplement. As CD4 is also expressed on other lymphocyte 
subpopulations, including dendritic cells, we first quantified 
what percentage of CD3+ T-cells is contained within the CD4+ 
population. Over 98% of CD4+ cells also expressed CD3 
(Figure V in the online-only Data Supplement). To reflect the 
physiological environment, the total splenocyte population 
was cocultured in the presence of T-cell–specific activation 
under conditions of physoxia or hyperoxia. After 14 days, 
total cell numbers of the individual subpopulations were quan-
tified by flow cytometry to extrapolate rates of proliferation. 
CD4+ T-cells displayed the greatest proliferative response with 
100-fold expansion for 14 days under 3% oxygen (Figure 1D) 
while a 3-fold increase in B-cell numbers (Figure 1E) and a 
7-fold increase in the CD11b+ population (including myeloid 
cells, granulocytes, and natural killer T-cells; Figure 1F) was 
observed during the same period. Importantly, only the prolif-
eration of CD4+ T-cells was significantly (P<0.01) attenuated 
by hyperoxia-induced oxidative stress. However, the CD11b+ 
were not experimentally stimulated to proliferate under these 
experimental conditions.
Oxidative Stress Impairs T-Cell Proliferation 
via Suppression of Telomerase
We next sought to identify the underlying mechanism by 
which hyperoxia attenuates T-cell proliferation. We have pre-
viously demonstrated that increased oxidative stress excludes 
the TERT protein from the nucleus of hTERT overexpressing 
fibroblasts, thereby preventing telomere maintenance and halt-
ing cell proliferation59 and that telomerase facilitates statin-
induced T-cell proliferation.47 The latter led us to hypothesize 
that the oxidative stress–induced attenuation of T-cell prolif-
eration in this study might be mediated via the suppression 
of telomerase activity. To test this hypothesis, we quantified 
telomerase activity in WT splenocytes cultured at either phy-
soxia or hyperoxia. Hyperoxia resulted in a significant reduc-
tion of telomerase activity, and all detectable telomerase 
activity was suppressed after 2 weeks of culture (P<0.0001; 
Figure 2A). Telomeric Repeat Amplification Protocol assay 
positive and negative controls are shown in Figure VI in the 
online-only Data Supplement.
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To specifically address the role of telomerase in mediat-
ing proliferation, we investigated the proliferative poten-
tial of splenocytes isolated from first generation (F1) TERT 
knockout mice, which lack expression of telomerase reverse 
transcriptase (Tert−/−), the catalytic subunit of telomerase.60 
Although these mice lack functional telomerase activity, 
they do not have significantly shorter telomeres than WT ani-
mals.47 No significant difference in the rates of proliferation in 
Figure 1. Oxidative stress leads to chronic interferon γ (INF-γ) expression and impairs proliferation of CD4 T-cell but not B-cells or myeloid 
cells. A, Total or CD4+ splenocytes were cultured at either 3% or 40% oxygen saturation for 10 d. Dihydroethidium (DHE) fluorescence 
was increased under hyperoxia. n=4 for each experimental group. B, CD4+ splenocytes were cultured for up to 6 d at either 3% or 40% 
oxygen saturation. IFN-γ transcript expression was significantly increased at all time points under hyperoxia as quantified by quantitative 
reverse transcription polymerase chain reaction. n=4 for each experimental group. C, 2×105 splenocytes were cultured per well at 3% or 
40% oxygen saturation. Total cell numbers were quantified at 3-d intervals. All error bars represent the SEMs (SD). n=4 for each experi-
mental group. D and F, Flow cytometry was used to identify and quantify individual cellular subpopulations of the splenocyte cell cultures. 
A total of 2×106 splenocytes/mL were cultured after T-cell–specific activation. Total numbers of each subpopulation were quantified by 
flow cytometry. n=3 for each experimental group, error bars (SD). *P<0.05, **P<0.01, ***P<0.001, and ****P<0.0001 using with Mann–Whit-
ney U test or 2-way ANOVA as appropriate.
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Figure 2. Oxidative stress decreases T-cell proliferation and suppresses telomerase. A, 2×106 splenocytes (n=5) were cultured for up to 
14 d at either 3% or 40% oxygen. T-cell–specific activation was achieved by coating plates with CD3 and CD28 antibodies. Telomeric 
Repeat Amplification Protocol assay was used to quantify telomerase activity in cells isolated at the 3, 5, 7, 10, and 14 d time points. 
n=4 for each experimental group. B, Splenocytes isolated from telomerase reverse transcriptase (TERT)−/− mice were cultured for up to 
27 d at either 3%, 20%, or 40% oxygen saturation, and total cell numbers were quantified at 2- to 4-d intervals. Dotted line indicates 
mean cell numbers for wild-type splenocytes after 28 d of cultivation at the same oxygen saturation. n=4 for each experimental group. 
C and D, CD4+ splenocytes from either TERT+/+ or TERT−/− mice were cultured at 2×105 cells/well under 3% or at 40% oxygen conditions 
for 14 d. T-cell–specific activation was maintained by addition of antibody-labeled beads at days 0, 7 and 14. n=3 for each experimental 
group. E and F, Total splenocytes from either TERT+/+ or TERT−/− mice were cultured at 1×106 cells/well under 3% in the presence of the 
telomerase activator TA-65 at indicated concentrations for up to 21 d. T-cell–specific activation was maintained (Continued )
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Tert−/− splenocytes cultured under physoxic or hyperoxic con-
ditions were observed (Figure 2B). Moreover, CD4+ T-cells 
immunomagnetically isolated from spleens of F1 Tert−/− mice, 
opposed to WT CD4+ cells (Figure 2C), also displayed no dif-
ference in proliferation rates when cultured in either hyper-
oxia or physoxia (Figure 2D). To further validate our findings, 
WT splenocytes were cultured in the presence of the small 
molecule telomerase activator TA-65.52 Activation of telom-
erase in cultured WT splenocytes significantly enhances 
proliferation in a dose-dependent manner (Figure 2E). As 
expected, even in the absence of TA-65, TERT−/− splenocytes 
demonstrate a decreased baseline proliferation compared 
with WT cells (Figure 2E and 2F) and failed to respond to 
TA-65 (Figure 2F). Finally, we investigated the effects of the 
specific telomerase inhibitor BIBR-153253 on splenocyte pro-
liferation at different oxygen saturation levels. Splenocytes 
demonstrated a dose-dependent attenuation of proliferation 
when treated with the inhibitor providing further evidence 
that telomerase activity seems to mediate proliferation when 
cultured at physoxia (Figure 2G). As expected, splenocytes 
cultured in hyperoxia demonstrated a reduced proliferation; 
however, BIBR 1532 treatment resulted in a significant dose-
dependent decrease in proliferation at 2 weeks even under 
these conditions (Figure 2H).
Having demonstrated that oxidative stress suppresses 
telomerase activity, we next aimed to ascertain whether this 
reduction in telomerase was at a transcriptional level of TERT 
expression. To investigate the effect of oxidative stress on 
mTERT expression at the single cell level, splenocytes were 
isolated from telomerase reverse transcriptase reporter mice 
(mTert-GFP)61 and cultured under the different oxygen con-
ditions (Figure 3A). Under physoxia, ≈15% of splenocytes 
expressed mTert-GFP at day 3 and expression decreased 
thereafter during ongoing cultivation (Figure VIIA and VIIB 
in the online-only Data Supplement). In contrast, hyperoxia 
significantly (P<0.0001) attenuated mTert-GFP expression in 
splenocytes at all time points investigated (Figure 3B) dem-
onstrating that oxidative stress inhibits mTert expression at 
a transcriptional level. We next evaluated the total number 
of mTert-GFP expressing cells and the percentage of mTert-
GFP expressing cells in individual splenocyte subpopulations 
(Figure 3C and 3D; gating strategy is shown in Figure IV in 
the online-only Data Supplement). mTert-GFP expression 
mimicked the proliferative trends of each cell subpopulation 
in the different oxygen conditions shown in Figure 2.
Telomerase-Deficient T
reg Cells With Long Telomeres 
Remain Protective Against Atherosclerosis
We have previously established that T
reg cells modulate the 
development of atherosclerosis in mice. Using adoptive trans-
fer studies, we demonstrated that naturally arising T
reg cells are 
potent inhibitors of atherosclerosis in several different mouse 
models.5 We next examined whether telomerase-deficient 
T
regs retain the potential to suppress atherosclerosis in vivo. 
Surprisingly, Tert−/− mice contained the same number of both 
CD4+ T-cells and T
reg cells, including the CD4+CD25+FoxP3+ 
population, as WT mice (Figure 4A–4C). Gating strategy 
and controls shown in Figure VIIC in the online-only Data 
Supplement. While acknowledging the potential variation 
introduced by the digestion protocol, we also quantified the 
total number of splenocytes obtained from each spleen for WT 
and TERT−/− mice. A significant reduction in the total number 
of cells isolated from TERT−/− was observed (Figure VIII in 
the online-only Data Supplement). To evaluate the functional 
properties of telomerase-deficient T-cells, we purified T
reg cells 
and CD4+CD25– effector T-cells and assessed their prolifera-
tive potential ex vivo (representative flow plots are shown in 
Figure IX in the online-only Data Supplement). T
reg cells were 
suppressive of effector T-cells proliferation, regardless of Tert 
expression (Figure 4D and 4E). Having identified that telom-
erase expression was not required for T
reg suppressive function 
ex vivo, we investigated the effect of oxidative stress specifi-
cally in this population in vitro (Figure 4F). Hyperoxia had no 
effect on the expansion of the CD25+ T
reg population but did 
significantly diminish proliferation of CD25– effector T-cells.
To ascertain whether TERT-deficient T
reg cells remain 
protective against atherosclerosis in vivo, we adoptively 
transferred a mixture of CD28−/− splenocytes, which lack the 
potential to differentiate into T
reg cells, together with either 
WT or Tert−/− T
regs into Rag2−/−ApoE−/− mice, which lack 
mature lymphocytes. No group of atherogenic Western diet–
fed mice displayed any difference in their weight (Figure 5A) 
and had the same elevated levels of cholesterol (Figure 5B). 
As expected, total and effector CD4+ T-cells among spleno-
cytes were the same in all 3 groups (Figure 5C) while T
regs 
were significantly higher in the adoptive transfer groups (15% 
versus 3%; P<0.001; Figure 5C and 5D). The same was true 
for T
reg content in lymph nodes (25% versus 4%; P<0.001; 
Figure 5D). For all subpopulation analyses, gating strategy 
and representative flow plots are shown in Figure XA and XB 
in the online-only Data Supplement. We assessed the athero-
sclerotic plaque area in the aorta after 7 weeks of Western diet 
feeding. TERT−/− T
regs were able to suppress plaque area to the 
same degree as WT T
regs (P<0.01; Figure 5E–5G).
Telomere Shortening Leads to Reduced Numbers 
of T
regs and Decreases Treg Cell Function
We next aimed to ascertain whether telomere attrition in the 
T
reg cell population affects their number and function. We 
have previously demonstrated that bone marrow hematopoi-
etic stem and progenitor cells from 12-month-old first gen-
eration (F1) TERC−/− mice had shorter telomeres compared 
with WT mice from the same strain (because of heterozy-
gotes that were used to generate TERT−/− mice already hav-
ing short telomeres).62 We compared the percentage of CD4+ 
T-cells and T
regs in the spleen of both these TERC−/− and WT 
Figure 2 Continued. by antibody-coated plates. n=3 for each experimental group. G, CD4+ splenocytes were cultured at 2×105 cells/well 
under 3% n=3 for each experimental group, or at (H) 40% oxygen conditions for 14 d n=4 for each experimental group. In the presence 
of BIBR 1532 (telomerase inhibitor) at indicated concentrations, T-cell–specific activation was maintained by addition of antibody-labeled 
beads (anti-CD3/CD28) at days 0, 7 and 13. All error bars represent the SD. *P<0.05, ****P<0.0001 using with Mann–Whitney U test or 
2-way ANOVA as appropriate. ns indicates nonsignificant.
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Figure 3. Oxidative stress suppresses telomerase at the level of mTert transcription. Splenocytes were isolated from mTert-GFP reporter 
mice and cultured for 14 d at 3% or 40%, and T-cell activation maintained on antibody-coated plates. mTert-GFP (green fluorescent pro-
tein) expression was quantified at a single cell level on 3, 4, 7, 10, and 14 d of cultivation by flow cytometry. A, Representative flow dot 
plots for the percentage of total mTert-GFP expressing cells at the indicated time points and at both conditions as a percentage of total 
cells. Gating was established using wild-type mice as controls with <0.1% positive events in the mTert-GFP+ gate. B, Absolute numbers 
of mTert-GFP–positive cells within the total splenocyte population over time as quantified by flow cytometry. n=4 for each experimental 
group. C, Absolute numbers of mTert-GFP–positive cells within individual splenocyte subpopulations over time as quantified by flow 
cytometry. n=4 for each experimental group. D, Percentage of the CD4 (top graph) and B-cell populations (bottom graph) that express 
mTert-GFP at each time point and condition. n=3 for each experimental group. All error bars represent the SD. *P<0.05, **P<0.01, 
***P<0.001, and ****P<0.0001 using 2-way ANOVA.
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mice (Figure 6A and 6B). Genetic knockout of TERC did not 
affect CD4+ T-cell numbers; however, it did result in a sig-
nificant reduction in the number of T
regs (CD4+CD25+Foxp3+; 
Figure 6B). In addition, we assessed the functional proper-
ties of TERC-deficient T
regs ex vivo. Surprisingly, unlike 
TERT-deficient cells (Figure 4D and 4E), TERC−/− T
reg cells 
Figure 4. Absence of telomerase reverse transcriptase does not affect the in vivo number or suppressive function of regulatory T-cell 
(Treg) cells in vitro. A–C, Flow cytometry was used to quantify CD4+ and Treg cell populations in the spleens of wild-type (WT) or telomer-
ase reverse transcriptase (TERT)−/− mice. n>4 for each experimental condition. D and E, CD4+CD25− effector T-cells (Teff) cells were iso-
lated and carboxyfluorescein diacetate succinimidyl ester (CFSE) labeled to allow quantification of proliferation by flow cytometry (CFSE 
is diluted during each cell division). Coculture with either WT or TERT−/− Treg cells suppressed Teff cell proliferation in a dose-dependent 
manner. n>5 for each experimental condition. F, CD25+/− cells were isolated from the spleen of WT mice and were cultured for up to 27 d 
at either 3% or 40% oxygen saturation, and total cell numbers were quantified at indicated intervals. n=3 for each experimental condition. 
Error bars represent SD. A 2-way ANOVA was used for statistical analysis.
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Figure 5. Regulatory T-cell (Treg) cells lacking telomerase reverse transcriptase remain protective against atherosclerosis. A, Rag2
–/– mice 
were transplanted with telomerase reverse transcriptase (TERT)−/−, wild-type (WT) Tregs, or no Tregs (control) and weighed daily. No sig-
nificant difference in weight was observed between any groups. B, Measurements of serum cholesterol. No significant difference was 
observed between groups. C and D, No difference in the number of viable CD4+ or Treg was observed within the lymph node and spleens 
of mice transferred with either WT or TERT−/− Tregs. Quantification performed by flow cytometry. E, Comparison of plaque area between 
Rag2–/– mice transplanted with WT Treg, TERT
−/− Tregs, or no Tregs. F and G, Representative images of plaques stained with Oil Red O in mice 
transplanted with TERT−/− Tregs or no Tregs. Yellow borders highlight plaque area. The data were obtained from 9 mice for each experimental 
group. Error bars represent SD. A Mann–Whitney U test or 2-way ANOVA was used for statistical analysis as appropriate.
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Figure 6. Telomerase RNA component (TERC)−/− mice have reduced regulatory T-cell (Treg) numbers with decreased suppressive function 
ex vivo. A, Flow cytometry was used to quantify CD4+ and Treg cell populations in the spleens of wild-type (WT) or TERC
−/− mice. n>5 for 
each experimental condition. B, Representative example of flow cytometry plot. C, CD4+CD25– effector T-cells (Teff) were isolated and 
carboxyfluorescein diacetate succinimidyl ester labeled to enable quantification of proliferation by flow cytometry. n=9 for each experi-
mental condition. Coculture with WT (C57BL/6J) but not TERC−/− Treg cells suppressed Teff cell proliferation in a dose-dependent manner. 
Error bars represent SD. A Mann–Whitney U test was used for statistical analysis.
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lacked suppressive function of effector T-cells proliferation 
(Figure 6C).
Discussion
Our data demonstrate that telomerase positively influences 
T-cell expansion; however, it is not required per se for base-
line proliferation or T-cell homeostasis. Evidence suggests 
that activated T-cells express high levels of telomerase activity 
to protect their telomeres from accelerated shortening, thereby 
evading replicative senescence.63 However, the contribution of 
telomerase activity to T
reg function had not been investigated 
to date.
The data we present in this study indicate that telomer-
ase expression is not required for T
reg suppressive function. 
Although absolute numbers of splenocytes may be decreased, 
mice with long telomeres that lack functional telomerase 
activity, like the F1 TERT−/− mice used in this study, maintain 
a T
reg population of relative comparable size to WT animals, 
which remains functional. Although T
regs express telomerase, 
it is possible that this cannot indefinitely maintain telomere 
length, particularly under conditions of oxidative stress that 
decreases telomerase activity. Interestingly, we have demon-
strated that TERC−/− mice with shorter haematopoietic stem 
and progenitor cell telomere length have a severe reduction in 
peripheral T
reg cell numbers in vivo and impaired function in 
vitro. This confirms that indeed it is a sufficiently long telo-
mere length rather than the mere presence of telomerase activ-
ity that is important for T
reg cell functioning.
For our studies, we have performed adoptive transfer exper-
iments using Rag2−/− ApoE−/− mice, as previously described.5 
These experiments require the transfer of CD28−/− splenocytes 
which have the potential to differentiate into all lineages of the 
adaptive immune system except T
reg cells. We are aware that 
although our study directly tested the functionality of TERT−/− 
T
reg cells in an in vivo disease model, the immune system may 
be compromised in this model. Further studies are required 
to determine whether more subtle phenotypes are apparent in 
alternative nonimmunocompromised models that lack TERT.
Multiple studies have confirmed the association of short 
leukocyte telomere length and the incidence of CHD in 
humans.64 Mendelian randomization studies in >200 000 par-
ticipants have also suggested that a genetic reduction of telo-
mere length (via mutations in TERT or TERC genes) leads to 
an increased risk of CHD.65 Although in our animal studies 
absence of telomerase had no effect on T
reg maintenance, it 
is important to point out that because of the long telomeres 
in laboratory mouse strains, this may not reflect the human 
biology of telomeres. Indeed, late-generation TERC knockout 
mice with shorter telomeres are considered more representa-
tive of the human situation.
It is known that the adaptive immune system plays a piv-
otal role in the development and progression of atherosclero-
sis.66 Although the proatherogenic function of T-helper type 
1 CD4+ as well as CD8+ T-cells is well established, it is also 
emerging that T
reg cells are critical in offsetting the detrimental 
effects of both adaptive and innate immune responses. What 
remains unclear is how the plaque environmental milieu influ-
ences the net effect of these 2 antagonistic responses and how 
the molecular mechanisms controlling the survival, prolifera-
tion, and suppressive function of the T
reg population contribute 
to disease progression. We propose that within the atheroscle-
rotic plaque, chronic oxidative stress conditions may lead to 
suppression of telomerase and acceleration of telomere attri-
tion in T
regs. This in turn may contribute to premature senes-
cence of T
reg cells and therefore progression of atherosclerosis.
Oxidative stress within the atherosclerosis microenviron-
ment may have other detrimental effects that could contribute 
to disease progression. Oxidative stress can directly damage 
both genomic DNA, in the absence of telomere shortening, 
and mitochondrial DNA, which is linked to vascular senes-
cence and atherosclerosis.67 Accumulated DNA damage in 
peripheral blood cells not only occurs in patients with CAD 
and acute myocardial infarction68 but is also associated with 
outcome.69 Moreover, high-cholesterol diet and atheroscle-
rosis have been associated with increased DNA damage in 
peripheral lymphocytes in rabbits.70 Mitochondrial localiza-
tion of the TERT protein has been demonstrated to regulate 
levels of mitochondrial derived reactive oxygen species and 
TERT can translocate to the mitochondria reducing mito-
chondrial derived reactive oxygen species production in the 
process which is independent of its canonical role in the 
nucleus.59 It had been shown in different cell types that lack of 
TERT specifically in the mitochondria is detrimental to mito-
chondrial function and morphology.71 However, such a mito-
chondrial role has to date not been described in immune cells. 
We and others have previously demonstrated that TERT can 
to bind to mitochondrial DNA which also protects cells from 
DNA damage and oxidative stress.71,72 An antioxidant role of 
TERT has also recently been described by Beyer et al53 who 
have demonstrated that loss of telomerase activity in cells of 
healthy human vessels results in a switch from nitrous oxide 
to a proinflammatory hydrogen peroxide, which mediates 
vascular dilation. Conversely, restoration of telomerase activ-
ity in arterioles from humans with CAD reverts the mediator 
of flow-induced dilation from hydrogen peroxide to nitrous 
oxide.53 The data in our current study demonstrate that oxi-
dative stress attenuates TERT expression at a transcriptional 
level in lymphocytes. Such reduction in telomerase influences 
both telomerase nuclear activity and would also diminish some 
noncanonical functions of telomerase and thereby resistance 
to oxidative stress further contributing to disease. Indeed, we 
have demonstrated that oxidative stress and attenuated TERT 
expression are both associated with an increased production 
of mitochondrial derived superoxide. We are currently investi-
gating the impact of telomerase activation by TA-65 on canon-
ical (telomere length) and noncanonical (oxidative stress and 
microvascular endothelial function) pathways in patients with 
myocardial infarction (TACTIC trial). Noncanonical roles for 
telomerase may possibly also explain the difference in phe-
notype between the TERT−/− and TERC−/− mice in addition to 
differences in telomere length that are already differentially 
regulated at the level of heterozygotes in both knockout mod-
els.73 The TERC−/− mice might still benefit from noncanonical 
roles of telomerase because of the presence of TERT.
Correlative evidence from human population studies 
collectively suggests an association of short telomeres in 
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lymphocytes with conditions of increased oxidative stress, 
including smoking, obesity, and CHD.27,28,32,33,74–76 Furthermore, 
nonimmune cells have been shown to have accelerated telo-
mere attrition and develop premature senescence when cul-
tured under hyperoxic conditions.18,47 This could represent one 
mechanism that would explain why patients with short telo-
meres in lymphocytes are predisposed to CHD, a hypothesis 
supported by our recent work demonstrating that immunose-
nescence can be an independent predictor of disease outcome 
in older people, possibly via accelerated atherosclerosis.77
The only study showing an atheroprotective effect of 
global telomerase deficiency as well as shortened telomeres 
in the ApoE mouse model38 may be explained by global 
immunosenescence and a dysfunctional immune system, 
where the lack of myeloid cell proliferation is responsible for 
reduced plaque progression. Of note, our experiments dem-
onstrate that in contrast to T-cells, proliferation of myeloid 
cells was indeed not influenced by oxidative stress. Therefore, 
the plaque environment seems to modulate the local immune 
response in a manner conducive for chronic inflammation. A 
dichotomous protective versus pathological role of telomer-
ase as a result of tissue specificity has already been described 
(reviewed in 78). Telomerase activation has been demon-
strated to reduce reactive oxygen species production and 
thereby inflammation in the endothelium whereas increased 
telomerase activity within the vascular smooth muscle layer 
can result in abnormal proliferation and vascular remodeling 
in hypertensive rats.78
Finally, even in light of recent studies demonstrating that 
critically short telomeres can be protective for atherosclero-
sis, our current data suggest that restoring telomerase activ-
ity in T-cells, for example, through small molecule activators 
such as TA-65,52,79 remains a potentially powerful therapeutic 
intervention.
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Highlights
• Hyperoxia induces oxidative stress and T-cell activation and reduced CD4+ T-cell proliferation in vitro.
• Oxidative stress–mediated reduction in CD4+ T-cell proliferation is telomerase reverse transcriptase dependent.
• Telomerase reverse transcriptase deficiency has no effect on regulatory T-cell (Treg) numbers in vivo or suppressive function of the 
Treg population ex vivo.
• Oxidative stress had no effect on the proliferation of the Treg subpopulation or CD11b
+ myeloid cells in vitro.
• Telomerase function was not required for the ability of Tregs to protect against atherosclerosis in vivo; however, telomere length is critical for 
Treg function.
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Major Resources Tables 
 
Animals 
Species/Strain Vendor or Source Background Strain Sex 
Wild type Charles river C57BL/6J Male and Female 
B6.129S-Tert, tm1Yjc/J 
(TERT-/-) 
Jackson 
Laboratory 
C57BL/6J Male and Female 
Cg-Terc tm1Rdp/J (TERC-/-) Jackson 
Laboratory 
C57BL/6J Male and Female 
mTert-GFP David Breault 
Harvard. 
C57BL/6J. 129S Male and Female 
Rag2-/- ApoE-/- double knock 
out 
Charlies River C57BL/6J Male and Female 
CD28-/- Charlies River C57BL/6J Male and Female 
 
Antibodies 
Target antigen Vendor or Source Catalog # Working 
concentration 
Lot # (preferred 
but not required) 
anti-CD4 (L3T4). 
For Isolation 
Miltenyi Biotec  130-049-201 As per 
manufacture 
instructions 
 
MACSibead mouse 
T-cell expansion 
beads 
Miltenyi Biotec 130-093-627 As per 
manufacture 
instructions 
 
Anti CD-3. For T 
cell activation 
BD Biosciences BD 553238 0.5ug/ml  
Anti CD-28. For T 
cell activation 
BD Biosciences BD 553295 0.5ug/ml  
CD45R (PerCP) BD Biosciences 553093 0.1 µg/ml  
CD11b (APC) BD Biosciences 561690 0.1 µg/ml  
CD4 (PE-Cy) BD Biosciences 552775 0.1 µg/ml  
CD8 (Pacific Blue) BD Biosciences 558106 0.1 µg/ml  
Treg Detection Kit Miltenyi Biotec 130-094-164 As per 
manufacture 
instructions 
 
CD4+CD25+ Treg 
isolation kit 
Miltenyi Biotec 130-091-041 As per 
manufacture 
instructions 
 
CD4 Biolegend 100531 1µg/ml  
CD25 Biolegend 102012 1µg/ml  
CD3 Biolegend 100321 2µg/ml  
CD62L Biolegend 104424 2.5µg/ml  
CD44 Biolegend 103012 0.5µg/ml  
Foxp3 Life Technologies 12-5773-82 2µg/ml  
 
 
SUPPLEMENTAL MATERIAL 
Supplementary Figure I 
 
0.8%
Negative control
16.3%
Pre CD4 purification step
79.4%
Post CD4 purification step
 
 
Supplementary Figure I. Example of assessment of CD4 cell purity after 
isolation CD4 magnetic sorting. 
 
 
 
 
 
 
 
 
Supplementary Figure II 
 
 
3%
40%
 
 
Supplementary Figure II. Hyperoxic culture leads to increased mitochondrial 
superoxide production. Total splenocytes were cultured at either 3% or 40% 
oxygen saturation for 6 days. Mitosox fluorescence was increased under hyperoxia 
compared to cells cultured under 3% oxygen as indicted by a shift in the mean and 
geomean values when analysed by flow cytometry. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure III 
 
 
 
Supplementary Figure III. Oxidative stress leads to increased IL2 expression. 
CD4+ splenocytes were cultured at 2x105 cells/well under 3% or at 40% oxygen 
conditions for up to 6 days.  IL2 transcript expression was significantly increased at 
1, 3 and 6 days under hyperoxia as quantified by qRT-PCR. All error bars represent 
the standard deviation N>4 for each experimental condition. *P<0.05, **P<0.01, 
***P<0.001 and ****P<0.0001 using A 2-WAY ANOVA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure IV 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure IV. Gating strategies. A) Cells were first discriminated from debris based on SSC vs FSC. FSC-H vs 
FSC-A was used to establish a singlet gate. Cells within the singlet gate were assessed for viability (DAPI exclusion). B) Gating 
strategy for quantification of CD4+/CD8+ T-cells, B cells (CD45R+), myeloid cells (CD11b+) and mTert-GFP. Quantification of 
subpopulations performed as shown. Gating set to florescence minus one controls (FMO). In some experiments mTert-GFP was 
quantified within each subpopulation following the initial gating. Wild type splenocytes stained with all antibodies were used to 
establish positive gate for GFP expression. C) Quantification of Treg populations isolated directly from spleens (As in Figure 4 A-C 
and Figure 6A). CD4+CD8+ cells where identified using florescence minus one (FMO) controls to set gating. For these plots the 
heading indicates the channel in which the absent fluorophore would have been detected and the name of the absent antibody.  
CD25+/-, CD25+ and CD25- where quantified as a percentage of the CD4+CD8+ population. 
Supplementary Figure V.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure V. Quantification of the percentage of CD3+ T-Cells in the CD4+ population in mouse spleen. 
Supplementary Figure VI. 
 
 
 
 
Supplementary Figure VI. TRAP assay controls. Positive control: telomerase expressing immortal fibroblast cell line 3T3. For 
negative control: Splenocytes isolated from the Tert-/- knockout mouse line. 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure VII 
 
 
Supplementary Figure VII. Oxidative stress suppresses telomerase at the level of mTert transcription. Splenocytes were 
isolated from mTert-GFP reporter mice and cultured for 14 days at 3% or 40% and T-cell activation maintained with antibody 
coated plates. mTert-GFP expression was quantified at a single cell level on days 3, 4, 7, 10 and 14 days by flow cytometry. 
Representative flow dot plots for the percentage of total mTert-GFP expressing cells at each time-point and condition as a 
percentage of total cells. Gating was established using wild type mice as controls with <0.1% positive events in the mTert-GFP+ 
gate.  
Supplementary Figure VIII. 
 
 
 
Supplementary Figure VIII. Absolute numbers of Splenocytes obtained during 
the digestion of each individual spleen. Following digestion viable cells where 
counted on a hemocytometer using Trypan blue exclusion to distinguish live cells. 
N>3 for each experimental condition. *P<0.05, **P<0.01 using a 1-WAY ANOVA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure IX 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure IX. Representative flow plots for CFSE proliferation 
assay. 
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Supplementary Figure X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure X. Gating strategies A) Identification and quantification 
of Treg (CD4+ GITR+ Foxp3+) or Teff (CD4+ CD62- CD44hi) in Rag2-/- mice.  Rag2-/- 
mice were transplanted with CD28-/- splenocytes and either wild type Treg,TERT-/- 
Treg cells or PBS as control (no transplanted Tregs). Cells isolated from either spleen 
or lymph nodes where gated for viability (DAPI). A) Viable cells were either i) 
analysed for Foxp3 vs CD4 antibody labelling or ii) Gated based on CD4 antibody 
staining followed by subsequent analysis for CD44 and CD62L. B) Representative 
example of flow cytometry plots of Treg (CD4+ GITR+ Foxp3+) or Teff (CD4+ CD62- 
CD44hi)  found in rag2-/- mice transplanted with CD28-/- splenocytes and either wild 
type Treg, TERT-/- Treg cells or PBS control (no transplanted Tregs). 
A 
B 
Supplementary Table I Details of mouse strain and genetics used in each 
study. 
Figure Subfigure Strain Genetics 
1 A C57BL/6J Wild type 
B C57BL/6J Wild type 
C C57BL/6J Wild type 
D C57BL/6J Wild type 
E C57BL/6J Wild type 
F C57BL/6J Wild type 
2 A  B6.129S-Tert, 
tm1Yjc/J 
Wild type littermates F1 
B B6.129S-Tert, 
tm1Yjc/J  
TERT-/- F1 
C B6.129S-Tert, 
tm1Yjc/J 
Wild type littermates F1 
D B6.129S-Tert, 
tm1Yjc/J 
TERT-/- F1 
E B6.129S-Tert, 
tm1Yjc/J 
Wild type litter mates F1  
F B6.129S-Tert, 
tm1Yjc/J 
TERT-/- F1 
G C57BL/6J Wild type 
F C57BL/6J Wild type 
3 A B6.129S mTert-GFP 
B B6.129S mTert-GFP 
C B6.129S mTert-GFP 
4 A B6.129S-Tert, 
tm1Yjc/J 
TERT-/- F1 or Wild type litter 
mates 
B B6.129S-Tert, 
tm1Yjc/J 
TERT-/- F1 or Wild type litter 
mates 
C B6.129S-Tert, 
tm1Yjc/J 
TERT-/- F1 or Wild type litter 
mates 
D Tregs   = B6.129S-
Tert, tm1Yjc/J 
 
Teff      = B6.129S-
Tert, tm1Yjc/J 
Tregs   = TERT-/- F1 or Wild 
type litter mates 
 
Teff      = Wildtype =litter mates 
E Tregs   = B6.129S-
Tert, tm1Yjc/J  
 
Teff      = B6.129S-
Tert, tm1Yjc/J 
Tregs   = TERT-/- F1 or Wild 
type litter mates 
 
Teff      = Wildtype litter mates 
F C57BL/6J Wild type 
5 A -G Recipient mice = 
C57BL/6 
 
CD28-/- Donor mice 
=  C57BL/6J 
 
Tregs = B6.129S 
 
Recipient mice = Rag2-/-
/ApoE-/- 
 
CD28-/- Donor mice =  CD28 
knock out 
 
Tregs = TERT-/- F1 or Wild 
type litter mates 
6 A B6.Cg-Terc,  
m1Rdp/J (Blasco et 
al.,131 1997). 
TERC-/- F1or Wild type litter 
mates 
B  B6.Cg-Terc,  
m1Rdp/J (Blasco et 
al.,131 1997). 
TERC-/- F1 or Wild type litter 
mates 
C  B6.Cg-Terc,  
m1Rdp/J (Blasco et 
al.,131 1997). 
TERC-/- F1 or Wild type litter 
mates 
 
Detailed Methods 
Splenocyte and CD4 cell isolation 
Splenocytes were isolated from mice spleens by Ficoll-hypaque density gradient 
(using Biochrom AG Biocoll L 6113/5) and prepared at 2x106/ml in supplemented 
RPMI 1640. For CD4+ cell Isolation, following splenocyte isolation, cells were 
labelled cells with anti-CD4 (L3T4) labelled magnetic MicroBeads (Millitenyi Biotec 
130-049-201) and passed through magnetic column. CD4+ expressing cells were 
flushed from the column and collected. To improve CD4+ T-cells purity, fraction the 
CD4 positive cell fraction was  cells again passed down the column two more times.       
Splenocyte cultures and growth curves 
Splenocytes were cultured in a 24-well plate (2x106 cells/2ml/well). Cultured cells 
were expanded using (50% volume) complete medium RPMI 1640 with 0.5 mmol/L 
2-mercaptoethanol, 25 mmol/L Hepes Buffer, 1.5µg/ml IL-2 (AE5212101, RD,USA)) 
and 10% FBS. MACSibead mouse T-cell expansion beads (Miltenyi 130-093-627) 
were added to the remaining medium at a ratio of 1:1 beads per cell (i.e. 4x106 cells 
and 4x106 beads/2ml) as described1. 50% of the volume of each sample was 
transferred to a new well every 2-3 days and 50% fresh medium added to maintain 
T-cell activation beads. Cells were counted under a microscope using the Neubauer 
chamber (hemocytometer) and Trypan blue exclusion to identify live cells. Cells were 
re-activated on a seven-day cycle. When the cell count reached 10x106 cells, the 
suspensions were collected, mixed and transferred to a 6-well plate. These were 
centrifuged to 50% volume and the supernatant aspirated. The cells were then re-
suspended in fresh medium. When the cell count reached 24x106 in the 6-well plate, 
they were transferred to a 50ml (25cm2) culture flask and re-suspended in 50ml complete 
mouse medium for further cell culture expansion. CD4+ T-cells were isolated by 
immunomagnetic bead-selection from total splenocytes.  CD4+ T-cells underwent a 
similar process. CD4+ T-cells were first cultured in a 96-well plate (2x105 cells/200µl/well) 
when the cell count reached 2x106 they were transferred to a 24-well plate (2x106/2ml/well). 
Following this, the same process was used as for the splenocyte expansion. T cells from 
either TERT+/+ or TERT-/- mice (n=3) were seeded at 2x105 cells/well (volume = 
200µl/well) in a 96-well plate. TA-65 activator (TA65®) is a telomerase activator 
purified from Astragalus membranaceous 2 and provided by TA-Science Inc., New 
York, USA). BIBR 1532 (Tocris Boscience), a telomerase inhibitor, 3 was dissolved in 
DMSO and used as the indicated concentration.  
Cell culture for analysis by flow cytometry 
For experiments requiring flow cytometry analysis, wild-type and Tert-/- mouse 
splenocytes (n=3 mice in of each genotype) were seeded at 1x106 cells/well in a 6-
well plate coated with anti-CD3 (BD 553238) and anti-CD28 (BD 553295) antibodies 
and DAPI exclusion to allow gating for viability At the end of experiments 
splenocytes were stained with four fluorochrome conjugated antibodies; CD45R 
(PerCP), Cd11b (APC), CD4 (PE-Cy) and CD8 (Pacific Blue) to determine the 
proportions of each cell type in a sample. In our hands, ≥98% of CD4+ T cells can be 
identified as T cells by CD3+ staining (data not shown). 
Flow cytometry  
All flow cytomertry was measured on FACSCanto II (BD) and analysed using 
FacsDiva software. 
DHE and Mitosox staining  
Dihydroethidium and Mitosox are established methods to measure superoxide 
levels. 4, 5 Cells were labelled with 10 µM dihydroethdium (Molecular probes) as 
described6 or 5 µM Mitosox Red (Molecular Probes). Flow cytometry was then used 
to measure the median fluorescence intensity of 200,000 cells in the appropriate 
channel compared to unstained controls. 
Quantification of mTert-GFP+ cells 
Cells were isolated from spleens of mTert-GFP mice (n>5 per experiment) using 
complete RF10 (RPMI 1640 with 0.5 mmol/L 2-mercaptoethanol, 25 mmol/L Hepes 
Buffer, 10% FBS). Lymphocytes were enriched using a Ficoll-Hypaque density 
gradient. 1x106 cells were collected and stained using anti-CD4, anti-CD8, anti-
CD11b and anti-CD45 antibodies at 0, 3, 5, 7, 10 and 14 days. For culture studies 
cells isolated and prepared from mTert-GFP mouse spleens, as above, and added to 
plates labelled with anti-CD3 (BD 555338) and anti-CD28 (BD 555727) at a 
concentration of 2x106 cells per well. Cells were cultured in complete RF10 with the 
addition of IL-2 (1.5 µg/ml) at either 3% or 40% oxygen. DAPI exclusion was used to 
allow gating for viability, GFP expression was quantified relative to the total CD4, 
CD8, CD11b or CD45 cell populations using a FACSCanto II, running FACSDiva 
software. For each experimental group/time-point 50,000 live events were collected. 
Negative wild type controls were used to establish gates for flow analysis. 
Quantitative PCR (qPCR) 
Total mRNA was isolated from cells and cDNA was transcribed using random 
primers and the GoScript™ Reverse Transcriptase kit (Promega). Gene transcripts 
were quantified using TaqMan qRT-PCR on an Applied Biosystems 7900HT Real-
Time PCR system. Assays were run in triplicate and IFN-gamma (Applied 
Biosystems primer no. MN01168134_M1, 1340467) and IL2 Applied Biosystems 
primer no (Mm00434256_m1 4331182) (transcript expression was quantified using 
the comparative CT relative to Rm18s (Applied Biosystems primer no 
Mm03928990_g1, 1341105) transcript expression. Data were analysed using Step 
One Software v2.0.  
TRAP-PCR ELISA 
Enzyme immunoassay for the semi-quantitative determination of telomerase activity 
was performed using Telomeric Repeat Amplification Protocol (TRAP) kit (Roche), 
as per the manufacturer’s instructions. 500ng protein lysate was used for each 
reaction. The Elisa was analysed at 450nm absorbance using an Omega 
spectrophotometer reader (BMG Labtech).  
Detection of Regulatory T cells  
Following splenocyte isolation cells were labelled using the Treg Detection Kit 
(Miltenyi Biotec, Auburn, CA) as per manufactures instructions. Briefly, cells were 
fixed, permeabilized, and labelled with anti-CD4-FITC (clone: GK1.5), anti- CD25-PE 
(7D4) and Anti-FoxP3-APC (3G3). DAPI exclusion was used to allow gating for 
viability. Labelled cells were analysed using a FACS Canto II (BD Biosciences) and 
FACS diva software (BD Biosciences). 
Isolation of T cells responder CD4+CD25- and Treg cells CD4+CD25+ 
Mouse CD4+CD25+ Treg cell populations were isolated from mouse PBMC 
suspension using a CD4+CD25+ Treg isolation kit, according to the manufacturer’s 
protocols (Miltenyi, UK).  Briefly, splenocytes were suspended in PBS containing 
0.5% BSA and 2 mmol/L EDTA (pH=7.2) and then incubated with a biotin-antibody 
cocktail against CD8a (Ly-2; isotype: rat IgG2a), CD11b (Mac-1; isotype: rat IgG2b), 
CD45R (B220; isotype: rat IgG2a), CD49b (DX5; isotype: rat IgM) and Ter-119 
(isotype: rat IgG2b) for 20 min at 4°C. Microbead-conjugated, antibiotin mAb 
(isotype: mouse IgG1) was added to allow depletion of non-CD4+ T cells. In parallel, 
the cells were stained with PE-labeled anti-CD25 mAb.  The cell suspension was 
loaded on a LD column (Miltenyi Biotec), which is placed in the magnetic field of a 
MACS separator, and then the unlabelled splenocytes were run through. The 
remaining fraction in the column is the enriched CD4+ T cells (CD4+CD25- / 
CD4+CD25+). For the isolation of CD4+CD25+ T cells, the PE-labelled CD25+ T cells 
in the enriched CD4+ T cell fraction were labelled magnetically with anti-PE 
MicroBeads and separated by MACS sorting.  
Carboxyfluorescein succinimidyl ester (CSFE) proliferation assay 
Purified responder T cells (CD4+CD25-) were re-suspended in PBS (0.1% BSA) at 2 
× 106 cells/ml and incubated with Carboxyfluorescein Diacetate Succinimidyl Ester 
(CFSE) (final concentration: 1µmol/L) for 7 min at 37°C. Cells were washed in cold 
PBS and re-suspended in culture medium for 15 min to stabilize the CFSE staining. 
CFSE staining was analyzed using a FACS Canto II (BD Biosciences) and FACS 
diva software (BD Biosciences). 
Treg Suppression assay 
Murine splenic CD4+CD25+ Treg cells were isolated from WT, TERT-/- and TERC-/- 
mice using a MACS sorting isolation kit as described above. The CD4+CD25– T cells 
were isolated and stained with CFSE to be used as responder T cells. 1×105 
responder cells (CD4+CD25–) were added per well in RPMI-1640 medium 
supplemented with 10% FCS and 1.5µg/ml IL-2 (R&D 202-IL) in 96-well, round-
bottomed plate which had been pre coated with anti CD3 (BD 553238) and CD28 
(BD 553295) at 1µl/ml PBS at 4°C. CD4+CD25+ Treg cells were subsequently added 
to each well at the indicated ratio. Cells were co-cultured in complete medium at 
37°C and 5% CO2 for 72 h. After incubation cells were harvested and the 
proliferation of CD4+ responder T-cells was measured on FACS Canto flow 
cytometer (BD Biosciences) and analysed with FACS diva software (BD 
Biosciences). 
Atherosclerosis experiments 
Rag2-/- ApoE-/- mice were transplanted with 107 splenocytes from CD28-/- mice and 
either PBS, or 106 CD4+ CD25+ regulatory T cells (isolated by magnetic separation 
as above) from either Tert-/- mice or wild type littermates. Mice were fed an 
atherogenic Western diet (21% fat, 0.15% cholesterol) for 7 weeks. Atherosclerosis 
was quantified in the aortic root as described previously7. Briefly, ten serial 
cryosections spanning the root were stained with Oil Red O. Microscope images 
were obtained and Oil Red O staining quantified using a Leica microscope and LAS 
AF software. Plasma cholesterol levels were measured using a commercial 
cholesterol kit (Biomerieux). 
Statistical Analysis 
Following a test for normality statistical analysis was performed as appropriate and 
indicated in the legend of each figure, data are presented as mean ± SEM or as dot 
for individual experiments with a line representing the median. A Mann-Whitney U-
Test was used to compare groups of two and two-way ANOVA with Bonferroni post-
hoc analysis was used to compare groups of three or more. Statistical significance 
was set at p<0.05. 
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